45720
Eserine salicylate salt
≥97.0% (N)
Synonym(s):
Physostigmine salicylate salt
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H21N3O2 · C7H6O3
CAS Number:
Molecular Weight:
413.47
EC Number:
200-343-8
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
3900576
MDL number:
Assay:
≥97.0% (N)
Form:
powder
biological source
synthetic
assay
≥97.0% (N)
form
powder
optical activity
[α]20/D −77±2°, c = 1% in ethanol
mp
181-183 °C
SMILES string
OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2
InChI
1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1
InChI key
HZOTZTANVBDFOF-PBCQUBLHSA-N
Biochem/physiol Actions
Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Inhalation - Acute Tox. 2 Oral
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
F Matschiner et al.
HNO, 49(12), 1026-1028 (2002-01-17)
Appearance of an anticholinergic syndrome after treatment with drugs in therapeutic dosages is seldom reported in the literature. Based on a case report, the development and course of an anticholinergic syndrome after treatment with dimenhydrinate are described. The drug was
F J Forno et al.
The Journal of the American Osteopathic Association, 98(9), 502-504 (1998-10-24)
Ingestion of jimsonweed can result in hallucinations. Despite this side effect, the differential diagnosis of jimsonweed toxicity can be difficult, in part, because routine drug screens do not detect this agent. Such a delay in diagnosis not only postpones treatment
A Bringmann
Neuroscience letters, 202(1-2), 13-16 (1995-12-29)
In previous experiments it was found that physostigmine application in unrestrained rats delayed the peak latency of the visual evoked potential (VEP). The present study was carried out to find the putative site that cholinergically mediates the latency delay of